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Abstract

Background Early experience with transcatheter
mitral valve replacement (TMVR) highlighted several
investigational challenges related to this novel therapy.
Conclusive randomised clinical trials in the field may,
therefore, be years ahead. In the interim, contemporary
outcomes of isolated surgical bioprosthetic mitral valve
replacement (MVR) can be used as a benchmark for the
emerging TMVR therapies.
Methods We used the nationwide inpatient sample
to examine recent trends and outcomes of surgical
bioprosthetic MVR for mitral regurgitation (isolated and
combined).
Results 21 007 patients who had bioprosthetic MVR
between 2003 and 2014 were included. Of those, 30%
had isolated MVR and 70% had concomitant cardiac
surgical procedure(s). In patients who underwent isolated
bioprothestic MVR, mean age was 68±13, and females
were the majority (58.4%). Most of these procedures were
performed at teaching institutions (71.3%) and during an
elective admission (64%). In-hospital mortality improved
during the study period (7.8% in 2003 to 4.7% in 2014,
p trend=0.016). Postoperative morbidities were common;
permanent pacemaker 11.7%, stroke 2.4%, new dialysis
4.9% and blood transfusion 41.6%. Mean length of stay
was 13±12 days, and 27.2% of patients were discharged
to an intermediate care of rehabilitation facility. Cost of
hospitalisation was $62 443±50 997.
Conclusions Isolated bioprosthetic MVR for mitral
regurgitation is performed infrequently but is associated
with significant in-hospital morbidity and mortality and
cost in contemporary practice. These data are useful as
benchmarks for the evolving TMVR therapies.

The steady success of transcatheter aortic
valve replacement (TAVR) has inspired an
explosion of clinical investigations aiming
at a matching success in transcatheter therapies for mitral regurgitation (MR), especially
in light of the consistent data showing that
MR is undertreated worldwide.1–3 Although
surgical treatment of MR has evolved to
primarily one of repair, not replacement,
early experience with transcatheter mitral
repair technologies suggested that a large
number of patients might be better suited

Key questions

What is already known about this subject?
►► Early experience with transcatheter mitral valve re-

placement (TMVR) identified certain challenges specific to this field. While conclusive randomised trials
in the field are under way, contemporary outcomes
of isolated surgical bioprosthetic MVR are lacking
and can be used as benchmarks for these emerging
TMVR therapies.

What does this study add?
►► In-hospital mortality of isolated bioprothestic MVR

improved overtime (7.8% in 2003 to 4.7% in 2014,
p trend=0.016), but surgery remained associated
with significant morbidity, lengthy hospitalisations
and high cost of care.

How might this impact on clinical practice?
►► These contemporary outcome data on isolated bi-

oprothestic mitral valve replacement may serve as
benchmarks for TMVR.

for transcatheter mitral valve replacement
(TMVR) than repair, fueling an increasing
interest in TMVR.2 There are currently >30
dedicated TMVR systems in development,
but only a handful have reached the early
feasibility study (EFS) stages.3
The first reports of TMVR with various
transcatheter platforms have raised concerns
about the safety of this therapy with an
average 30-day mortality rate of 23%.4 Nevertheless, the EFS of TMVR with the Tendyne
valve (Abbott, Roseville, Minnesota, USA) has
recently reported very promising outcomes
with an impressively low 30-day mortality at
3.3%.5 Due to the complexity of mitral valve
disease and the wide variability in its management, clinical trials of TMVR are expected
to face several challenges.6 In the interim,
contemporary data on surgical MVR in
patients with MR may serve as a benchmark
for further investigations in the expanding
TMVR field.3 4 7 We aim to use a nationwide
representative sample to assess characteristics
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Study flow chart.

and outcomes of patients with MR undergoing isolated
bioprosthetic MVR in the USA between 2003 and 2014.
Methods
The Nationwide Inpatient Sample (NIS) was used to
derive patient-relevant information between January
2003 and December 2014. The NIS is the largest publicly
available all-payer administrative claims-based database
and contains information about patient discharges from
approximately 1000 non-federal hospitals in 45 states. It
contains clinical and resource utilisation information on
5–8 million discharges annually, with safeguards to protect
the privacy of individual patients, physicians and hospitals. These data are stratified to represent approximately
20% of US inpatient hospitalisations across different
hospital and geographic regions (random sample).
National estimates of the entire US hospitalised population were calculated using the Agency for Healthcare
Research and Quality sampling and weighting method.
The institutional review board approved the study and
waived informed consent requirements because the data
are derived from a nationwide deidentified database.
We used (International Classification of Diseases-Ninth
Revision-Clinical Modification procedure code 35.23) to
select patients aged 40 years and older who underwent
bioprosthetic MVR during the study period. Patients who
underwent redo valve surgery (codes 35.95), those with
mitral stenosis (codes 394.0) or infective endocarditis
(codes 421, 42.10, 42.11, 42.19, 03642, 09884, 11281,
1154) or had codes for mitral valve repair or mechanical
MVR during the same admission were excluded (figure 1).
The outcomes of patients who underwent isolated valve
replacement were then studied and compared with those
of patients submitted for valve replacement combined
with other cardiac surgery.
The trends of bioprosthetic MVR for MV during
the 12-year study period were assessed using weighted
numbers (national estimates). Baseline patients’ comorbidities and procedural characteristics were described
for both the isolated and combined MVR groups. Trends
of in-hospital mortality during the study period for
both groups were described. Trend weights accounting
2

Results
Between 2003 and 2014, 21 007 patients who underwent
bioprosthetic MVR for MR (representing a national estimate of 103 709 patients), were included in our study. Of
those, 14 727 (70.1%) underwent a concomitant cardiac
surgical procedure. Utilisation of MVR for MR did not
change significantly during the study period (figure 2).
Patients who underwent a combined cardiac surgery
were older (71±10 vs 68±13 years, p<0.001), had higher
incidences of diabetes, atrial fibrillation, coronary and
peripheral vascular disease, and chronic renal disease
than those who underwent isolated MVR. However,
history of sternotomy was more common in the isolated
MVR group (table 1). Among patients who underwent
combined MVR, coronary artery bypass grafting was the
most common concomitant procedure (51.3%) followed
by aortic valve replacement (31.5%) and Cox-Maze
ablation (26.4%). There was a temporal trend towards
treating sicker patients overtime evident by the increasing
prevalence of key morbidities in both groups during the
study period (online supplementary e-tables 1,2).
Outcomes of isolated MVR
Among patients who underwent isolated MVR, in-hospital mortality was 6.1%, but improved significantly
during the study period from 7.8% in 2003 to 4.7% in
2014 (ptrend=0.016) (figure 3). Stroke occurred in
2.4%, vascular complications requiring surgical repair
in 1.9% and new dialysis was required in 4.9% (table 2).
Berzingi C, et al. Open Heart 2018;5:e000820. doi:10.1136/openhrt-2018-000820
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Figure 1

for changes in the NIS sampling design are only available for data between 1998 and 2011. For 2012 and
2014, trend weights were not available, and the standard
survey weights were used. To estimate the cost of hospitalisation, the NIS data were merged with cost-to-charge
ratios available from the Healthcare Cost and Utilization
Project. We estimated the cost of each inpatient stay by
multiplying the total hospital charge with cost-to-charge
ratios. Postoperative morbidities, length of stay (LOS),
disposition patterns and cost of care were also evaluated. Patient-relevant descriptive statistics are presented
as frequencies with percentages for categorical variables
and as means with SD for continuous variables. Baseline
characteristics were compared between the groups using
a Pearson χ2 test for categorical variables and an independent-samples t-test for continuous variables. Trends
over time were examined using a Mann-Kendall test for
trend (a non-parametric test to determine the presence
and direction of a trend over time). All statistical analyses
were performed using SPSS V.24 (IBM).
We also sought to identify independent predictors
of in-hospital mortality in our study cohort. Hence, we
entered 22 clinical, procedural and hospital characteristics into univariate and multivariate logistic regression
models to assess their possible predictive value of in-hospital mortality after valve surgery (online supplementary
e-table 1,2).

Valvular heart disease

Also, 11.7% had a permanent pacemaker implantation
postoperatively and 41.6% had blood transfusion. There
was a temporal trend towards lower incidence of permanent pacemaker implantation, but higher incidences of
dialysis-requiring acute kidney injury and stroke during
the study period (figure 4). Hospital LOS was >5 days in
84.9% of patients with mean LOS of 13±12 days. Most
patients were discharged home versus to intermediate
care facility (66.1% vs 27.7%, p<0.001). Mean cost of
hospitalisation was $62 443±50 997.
Outcomes of combined MVR
Among patients who underwent MVR concomitant with
other cardiac surgery, in-hospital mortality was 9.4%
overall, but also improved during the study period (13.4%
in 2003 to 8.3% in 2014, p trend=0.013) (figure 3). In
these patients, stroke occurred in 2.6%, vascular complications requiring surgical repair in 2.3% and new dialysis was initiated in 4.9%. Permanent pacemakers were
implanted in 14.3% postoperatively. There was no statistically significant change in the rates of major postoperative morbidities in this cohort (figure 4). Approximately
90% of patients stayed in the hospital over 5 days, with
a mean LOS of 15±14 days. Intermediate care facilities
were used in 35.4%. Mean cost of hospitalisation was $75
469±57 052.
Predictors of in-hospital mortality
Multivariate logistic regression analyses were performed
to identify predictors of in-hospital mortality in both
groups. Variables included in the regression model
included demographic and clinical characteristics,
hospital attributes and insurance status. Among patients
who underwent isolated MVR, the strongest predictors
of in-hospital mortality were the need for ventricular
assist device (OR 6.05, 95% CI 4.66 to 7.84), chronic
renal failure (OR 2.42, 95% CI 1.88 to 3.12), liver disease
(OR 2.27, 95% CI 1.15 to 4.47) and female gender (OR
1.65, 95% CI 1.31 to 2.08). Other predictors are shown
in online supplementary e-table 1. Among patients who
Berzingi C, et al. Open Heart 2018;5:e000820. doi:10.1136/openhrt-2018-000820

underwent MVR concomitant with other cardiac surgery,
the strongest predictors of in-hospital mortality were the
need for ventricular assist device (OR 5.31, 95% CI 4.62
to 6.09), liver disease (OR 3.02, 95% CI 2.14 to 4.25),
concomitant tricuspid valve replacement (OR 2.01, 95%
CI 1.39 to 2.92) and chronic renal failure (OR 1.83, 95%
CI 1.58 to 2.13). Other significant predictors are shown
in online supplementary e-tables 3,4.
The impact of gender on in-hospital outcomes
Females constituted the majority of patients undergoing
MVR in this study, especially in the isolated MVR group.
Compared with males, females who underwent MVR
were less likely to be of white race and less likely to have
chronic renal disease, coronary artery disease and prior
sternotomy, but had higher prevalence of chronic obstructive lung disease and anaemia (online supplementary
e-table 5. In-hospital mortality was higher in females than
in males following isolated and combined MVR (6.9% vs
5.0%, p=0.001, and 9.9% vs 8.8%, p=0.022, respectively).
Females had higher incidences of acute kidney injury
and blood transfusion, but similar rates of postoperative
strokes and permanent pacemaker implantation (online
supplementary e-table 6). Females also experienced
longer length of stay, were more likely to be discharged
to an intermediate care facility and accrued higher cost
of the hospitalisation. In a multivariate logistical regression analysis adjusting for 22 demographic, clinical and
hospital characteristics, female gender remained a significant independent predictor of in-hospital mortality (OR
1.65, 95% CI 1.31 to 2.08 for isolated MVR, and OR 1.31,
95% CI 1.15 to 1.48 for combined MVR) (online supplementary e-tables 1,2).
Discussion
The main findings of the present study are (1) MVR for
MR remains uncommon and is performed in conjunction with other cardiac surgery procedure in the majority
of cases. (2) Patients who undergo MVR for MR have high
3
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Figure 2 Utilisationt trends of bioprosthetic mitral valve replacement (MVR) for mitral regurgitation in the USA between 2003
and 2014.
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Characteristic
Age, mean (SD), years

All patients
(N=21 007
NE=103 709)

Combined MVR
(N=14 727
NE=72 680)

Isolated MVR
(N=6280
NE=31 029)

70 (11)
11 511 (54.8)

71 (10)
7843 (53.3)

68 (13)
3668 (58.4)

 White

13 946 (79.2)

9965 (80.8)

3981 (75.5)

 Black

1392 (7.9)

809 (6.6)

583 (11.1)

 Hispanic

1101 (6.3)

733 (5.9)

368 (7)

Female, n (%)
Race, n (%)

P values
<0.001
<0.001
<0.0001

Medical comorbidity, n (%)
 Hypertension

11 893 (57)

 Diabetes

4435 (21.1)

 Prior sternotomy

1265 (6)

8371 (57.2)

3522 (56.5)

0.337

3272 (22.2)

1163 (18.5)

<0.001

612 (4.2)

653 (10.4)

<0.001

5097 (24.3)

3565 (24.2)

1532 (24.4)

13 484 (64.2)

9970 (67.7)

3514 (56)

 Anaemia

4095 (19.5)

2855 (19.4)

1240 (19.7)

0.548

 Coagulopathy

6151 (29.5)

4600 (31.4)

1551 (24.9)

<0.001

469 (3.2)

152 (2.4)

<0.001

 Chronic pulmonary disease
 Atrial fibrillation/flutter

 Conduction abnormalities

621 (3)

0.771
<0.001

 Peripheral vascular disease

2125 (10.1)

1663 (11.3)

462 (7.4)

<0.001

 Chronic renal disease

3476 (16.5)

2492 (16.9)

984 (15.7)

0.025

120 (1.9)

0.491

1569 (25)

<0.001

381 (1.8)

261 (1.8)

9734 (46.3)

8165 (55.4)

41 (0.2)

27 (0.2)

14 (0.2)

0.55

 Liver disease

360 (1.7)

250 (1.7)

110 (1.8)

0.777

 Liver cirrhosis

148 (0.7)

108 (0.7)

40 (0.6)

0.444

Concomitant procedures, n (%)
 Percutaneous coronary
intervention

241 (1.1)

241 (1.6)

0 (0)

 Coronary artery bypass

7562 (36)

7562 (51.3)

0 (0)

<0.001

 Aortic valve replacement

4636 (22.1)

4636 (31.5)

0 (0)

<0.001

 Haemodialysis
 Coronary artery disease
 Metastatic cancer

<0.001

268 (1.3)

268 (1.8)

0 (0)

<0.001

 Tricuspid valve repair

1279 (6.1)

1279 (8.7)

0 (0)

<0.001

 Cox-Maze ablation

3883 (18.5)

3883 (26.4)

0 (0)

<0.001

 Left atrial appendage ligation

2189 (10.4)

2189 (14.9)

0 (0)

<0.001

 Open ASD/VSD repair

1147 (5.5)

1147 (7.8)

0 (0)

<0.001

 IABP/LV assist device use

2257 (10.7)

1785 (12.1)

472 (7.5)

<0.001

14 726 (70.2)

10 262 (69.8)

4464 (71.3)

0.035

1464 (7)

1033 (7)

431 (6.9)

 Tricuspid valve replacement

Hospital characteristics, n (%)
 Teaching hospital
 Hospital bed size
  Small
  Medium
  Large
 Rural location
 Non-elective admission status,
n (%)
 Surgery on day 0–1 of admission

0.478
3785 (18.1)
15 719 (75)
456 (2.2)
8141 (38.8)
11 221 (53.4)

2682 (18.2)

1103 (17.6)

10 988 (74.7)

4731 (75.5)

329 (2.2)

127 (2)

5883 (40)

2258 (36)

7569 (51.4)

3652 (58.2)

0.339
<0.001
<0.001
Continued
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Table 1 Characteristics of patients undergoing surgical bioprosthetic mitral valve replacement (MVR) for mitral regurgitation
between 2003 and 2014

Valvular heart disease
Continued

Characteristic

All patients
(N=21 007
NE=103 709)

Combined MVR
(N=14 727
NE=72 680)

Isolated MVR
(N=6280
NE=31 029)

16 243 (77.3)

11 628 (79)

4615 (73.5)

Primary payer, n (%)
 Medicare/Medicaid

<0.0001
4015 (19.1)

2612 (17.7)

351 (1.7)

228 (1.5)

 1.0–25th percentile

4658 (22.7)

3235 (22.5)

1423 (23.2)

 2.26–50th percentile

5168 (25.1)

3659 (25.4)

1509 (24.6)

 3.51–75th percentile
 4.76–100th percentile

5162 (25.1)
5562 (27.1)

3637 (25.2)
3876 (26.9)

1525 (24.8)
1686 (27.4)

 Private including HMO
 Self-pay/no charge/other

P values

1403 (22.3)
123 (2)

Median household income, n (%)

<0.0001

ASD, atrial septal defect; IABP, intra-aortic balloon pump; LV, left ventricular; NE, National Estimate; VSD, ventricular septal defect.

Figure 3 Trend of mortality for patients′ bioprosthetic mitral
valve replacement (MVR) for mitral regurgitation between
2003 and 2014.

demonstrated safety and efficacy in treating severe MR
in strictly selected patients with suitable anatomy, but also
highlighted the need for further devices to treat wider
ranges of MR pathologies.1 This has further fuelled the
interest in TMVR with several systems currently in EFS
phases. However, investigational challenges in the TMVR
field arose due to the complexity and the variability of
MV disease and its treatment options.3 For example, it
is unclear whether future randomised trials of TMVR
would randomise patients against medical therapy or
surgical MVR. Also, enrolling patients who are suitable
for MitraClip or surgical repair might be challenging.
Therefore, conclusive randomised evidence on TMVR
could be several years ahead. Current outcomes of
isolated bioprosthetic MVR in patients with MR may
therefore serve as a benchmark for future investigations.
Nevertheless, the existing literature on MVR includes
heterogeneous groups of patients with mechanical MVR,
infective endocarditis, mitral stenosis and those who are
undergoing redo mitral valve operations.7 10–13 In this
study, we attempted to identify a group of patients who
are similar to those that may be eligible for TMVR (those
who are undergoing isolated bioprosthetic MVR for MR).
Several intriguing observations can be made by
analysing the patient’s and procedural characteristics in
our study: (1) there was a very modest non-significant
increase in the number of bioprosthetic MVRs for MR
during the study period, contrary to the sharp increase
in surgical treatment of other valvular diseases during
the same period. (2) Patients who undergo MVR in the
current era have high-risk features including a significant prevalence of comorbid conditions (hypertension,
diabetes, anaemia, atrial fibrillation, prior sternotomy,
coronary artery disease, coagulopathy and chronic renal
insufficiency), and the prevalence of these comorbidities increased overtime, suggesting an increasing trend
to treated sicker patients. (3) The majority of patients
with MR undergo MVR concomitant with other cardiac
surgical procedures, with coronary artery bypass grafting

Berzingi C, et al. Open Heart 2018;5:e000820. doi:10.1136/openhrt-2018-000820

5

prevalence of significant clinical morbidities, and this
prevalence increased overtime (3) In-hospital mortality
following MVR for MR is high but has improved between
2003–2014. However, major post-operative morbidities
remained frequent and did not significantly change
overtime in the combined MVR group, while the rates of
stroke and acute kidney injury increased overtime in the
isolated MVR group. (4) MVR for MR is associated with
long hospitalizations, frequent intermediate care facility
utilisation and significant cost. (5) In this large cohort of
patients undergoing MVR, certain patient’s, hospital and
procedural characteristics were predictive of in-hospital
mortality.
Surgical treatment of MR remains underused due to
the surgical risk in many of MR patients and the lack
of solid clinical data supporting mitral valve surgery
for certain indications (eg, secondary MR).8 9 Over the
past decade, transcatheter mitral valve therapies have
emerged as promising alternatives to surgery in selected
patients and is hoped to expand treatment options in
this undertreated population. The MitraClip device
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Table 1

Open Heart

All patients
(N=21 007
NE=103 709)
Clinical outcome, n (%)
 In-hospital death
  Vascular complications
 Vascular complications requiring surgery
 Permanent pacemaker implantation
 Clinical stroke
 Acute kidney injury
 Acute kidney injury requiring dialysis
 Blood transfusion
 Cardiac tamponade
  Pneumonia
 Prolonged ventilation
  Wound infection
 Pulmonary embolism
 Deep venous thrombosis
Discharge status, n (%)
 Discharged home
 Discharged SNF/NH/IC
Length of stay, mean (SD), days
Length of stay >5 days
Cost of hospitalisation, mean (SD), $

Combined MVR
(N=14 727
NE=72 680)

Isolated MVR
(N=6280
NE=31 029)

1765 (8.4)
903 (4.3)
473 (2.3)
2836 (13.5)
533 (2.5)
4844 (23.1)
1028 (4.9)
8472 (40.3)
212 (1)
1347 (6.4)
1842 (8.8)
311 (1.5)
68 (0.3)
158 (0.8)

1381 (9.4)
645 (4.4)
354 (2.4)
2104 (14.3)
381 (2.6)
3659 (24.8)
723 (4.9)
5860 (39.8)
163 (1.1)
999 (6.8)
1339 (9.1)
243 (1.7)
44 (0.3)
102 (0.7)

384 (6.1)
258 (4.1)
119 (1.9)
732 (11.7)
152 (2.4)
1185 (18.9)
305 (4.9)
2612 (41.6)
49 (0.8)
348 (5.5)
503 (8)
68 (1.1)
24 (0.4)
56 (0.9)

12 258 (58.4)
6935 (33.1)
15 (13)
91 891 (88.6)
71 628 (55 652)

8117 (55.2)
5199 (35.4)
15 (14)
65 532 (90.2)
75 469 (57 052)

4141 (66.1)
1736 (27.7)
13 (12)
26 359 (84.9)
62 443 (50 997)

P values
<0.001
0.375
0.023
<0.001
0.482
<0.001
0.871
0.015
0.03
0.001
0.011
0.002
0.33
0.126
<0.0001

<0.001
<0.001
<0.001

IC, intermediate care; NE, National Estimate; NH, nursing home; SNF, skilled nursing facility.

being the most common one. Interestingly, concomitant
tricuspid valve repair/replacement was undertaken in
<10% of patients although moderate/severe tricuspid
regurgitation exists in 25% of patients with MR of any
aetiology and >50% of patients with secondary MR.3 14 15
In-hospital death occurred in 6.1% and 9.4% of MR
patients undergoing isolated and combined MVR,
respectively. Although this study included patients across
a wide spectrum of risk profiles, it does suggest that even
in ‘all-comers’ MVR for MR is associated with significant
in-hospital mortality. This highlights the importance
of the evolving TMVR field in addressing the critical
need to find less morbid alternatives for MR patients. It
also emphasises the contrast between aortic and mitral
valve diseases. In a contemporary nationwide analysis
of surgical aortic valve replacement, average in-hospital
mortality rate in all-comers was 2.5%.16 Rates of postoperative morbidities were also high:~5% of patients had
a dialysis requiring acute kidney injury,>10% required
permanent pacemaker implantation and >40% had
blood transfusion. There was also no temporal improvement in the incidence of acute kidney injury and stroke
in the combined MVR group, while the occurrence of
these complications increased in the isolated MVR overtime (online supplementary efigure-2). These data might
be useful when interpreting the emerging literature of
the very early experience with TMVR.
6

Cost and resource utilisation are becoming increasingly important in the era of healthcare reform. Being
the first widely adopted transcatheter valve therapy,
TAVR was under special scrutiny due to its added
incremental costs, but has been found cost-effective in
high-risk and inoperable patients.17–19 Emerging TMVR
systems have to be cost-effective to survive an increasingly value-driven healthcare delivery system. Our data
suggest that MVR is associated with long hospitalisations, significant cost and high rates of intermediate
care facility utilisation. Indeed, cost of MVR in our
study was over twofold higher than cost of aortic valve
replacement in a contemporary national cost analysis.20
These data suggest that future TMVR system can be very
competitive from a cost stand of point. In the largest
published EFS on TMVR to date, LOS was 9.7±5.9 days
even though the trial enrolled patients who are at high
or prohibitive risk for MVR.5
Limitations
Our study has several limitations. The NIS is derived
from hospital claims data without access to individual
medical records and subject to the shortcomings of
administrative datasets. However, the Healthcare Cost
and Utilization Project (HCUP) quality control measures should minimise these possibilities. Aetiology
of MR (primary vs secondary), Society of Thoracic
Berzingi C, et al. Open Heart 2018;5:e000820. doi:10.1136/openhrt-2018-000820
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Table 2 Clinical outcomes of patients undergoing surgical bioprosthetic mitral valve replacement (MVR) for mitral
regurgitation between 2003 and 2014

Valvular heart disease

Conclusions
Despite temporal improvement in operative mortality,
isolated bioprosthetic MVR for mitral regurgitation
remains associated with high morbidity and mortality and
cost in contemporary practice. These data are useful as
benchmarks for the emerging TMVR therapies.
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